Journal of Bone and Mineral Research · 2015 · 189 citations · 39 references
MedicineEndocrinologyInternal MedicineBone MetabolismDiabetologyNeuromusculoskeletal AssessmentBone BiomechanicsBone HealthBone QualityBone Quality AssessmentDiabetes MellitusMetabolic Bone DiseaseBone MicroarchitectureBone Mineral DensityBone Mineral Density AssessmentBone Quality IndicesBone StrengthBone Strength AssessmentBone Strength EstimationRadiographic Bone Measurement
The primary goal of this cross-sectional in vivo study was to assess peripheral bone microarchitecture, bone strength, and bone remodeling in adult type 1 diabetes (T1D) patients with and without diabetic microvascular disease (MVD+ and MVD-, respectively) and to compare them with age-, gender-, and height-matched healthy control subjects (CoMVD+ and CoMVD-, respectively). The secondary goal was to assess differences in MVD- and MVD+ patients. Fifty-five patients with T1DM (MVD+ group: n = 29) were recruited from the Funen Diabetes Database. Dual-energy X-ray absorptiometry (DXA), high-resolution peripheral quantitative computed tomography (HR-pQCT) of the ultradistal radius and tibia, and biochemical markers of bone turnover were performed in all participants. There were no significant differences in HR-pQCT parameters between MVD- and CoMVD- subjects. In contrast, MVD+ patients had larger total and trabecular bone areas (p = 0.04 and p = 0.02, respectively), lower total, trabecular, and cortical volumetric bone mineral density (vBMD) (p < 0.01, p < 0.04, and p < 0.02, respectively), and thinner cortex (p = 0.03) at the radius, and lower total and trabecular vBMD (p = 0.01 and p = 0.02, respectively) at the tibia in comparison to CoMVD+. MVD+ patients also exhibited lower total and trabecular vBMD (radius p = 0.01, tibia p < 0.01), trabecular thickness (radius p = 0.01), estimated bone strength, and greater trabecular separation (radius p = 0.01, tibia p < 0.01) and network inhomogeneity (radius p = 0.01, tibia p < 0.01) in comparison to MVD- patients. These differences remained significant after adjustment for age, body mass index, gender, disease duration, and glycemic control (average glycated hemoglobin over the previous 3 years). Although biochemical markers of bone turnover were significantly lower in MVD+ and MVD- groups in comparison to controls, they were similar between the MVD+ and MVD- groups. The results of our study suggest that the presence of MVD was associated with deficits in cortical and trabecular bone vBMD and microarchitecture that could partly explain the excess skeletal fragility observed in these patients.
39
A. M. Parfitt, Catharina H. E. Mathews, A. R. Villanueva et al. · Journal of Clinical Investigation · 1983 · 1.5K citations · Full text
Stéphanie Boutroy, Mary Bouxsein, F. Munoz et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 1.2K citations · Full text
Medicine, Radiology, Bone Metabolism +16
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Kenneth G. Saag, Elizabeth Shane, Steven Boonen et al. · New England Journal of Medicine · 2007 · 908 citations · Full text
Bone Loss and Bone Turnover in Diabetes
Jesse C. Krakauer, Malachi J. McKenna, Nancy Fenn Buderer et al. · Diabetes · 1995 · 475 citations